LabCorp(R) Scheduled to Present at the Merrill Lynch Health Services Conference

Apr 11, 2001, 01:00 ET from Laboratory Corporation of America Holdings

    BURLINGTON, N.C., April 11 /PRNewswire/ -- Laboratory Corporation of
 America(R) Holdings (LabCorp(R)) (NYSE:   LH) today announced that
 Thomas P. Mac Mahon, chairman and chief executive officer, is scheduled to
 speak at the Merrill Lynch Health Services Conference in Washington, DC on
 Wednesday, April 11.
     At the conference, Mr. Mac Mahon will reiterate Company guidance for 2001,
 as filed in an 8K on February 14, 2001.  Mr. Mac Mahon will state,  "We expect
 revenue growth of 10 percent to 11 percent, with a bad debt rate of
 9.7 percent of sales, EBITDA margins of approximately 20.5 percent to
 21 percent of sales, and EPS growth of approximately 45 percent to
 50 percent."
     The first clinical laboratory to fully embrace genomic testing, Laboratory
 Corporation of America(R) Holdings (LabCorp(R)) has been a pioneer in
 commercializing new diagnostic technologies.  As a national laboratory with
 annual revenues of $1.9 billion in 2000 and over 18,000 employees, the company
 offers more than 4,000 clinical tests ranging from simple blood analyses to
 sophisticated molecular diagnostics.  Serving over 200,000 clients nationwide,
 LabCorp leverages its expertise in innovative clinical testing technology with
 its Centers of Excellence.  The Center for Molecular Biology and Pathology, in
 Research Triangle Park (RTP), North Carolina, develops applications for
 polymerase chain reaction (PCR) technology.  LabCorp's National Genetics
 Institute in Los Angeles is an industry leader in developing novel, highly
 sensitive PCR methods for testing hepatitis C and other infectious agents, and
 its Center for Esoteric Testing in Burlington, North Carolina, performs the
 largest volume of specialty testing in the network.  LabCorp's clients include
 physicians, state and federal government, managed care organizations,
 hospitals, clinics, pharmaceutical and Fortune 1000 companies, and other
 clinical laboratories.
     Each of the above forward-looking statements is subject to change based on
 various important factors, including without limitation, competitive actions
 in the marketplace and adverse actions of governmental and other third-party
 payors.  Further information on potential factors that could affect LabCorp's
 financial results is included in the Company's Form 10-K for the year ended
 December 31, 2000 and subsequent SEC filings.
 
 

SOURCE Laboratory Corporation of America Holdings
    BURLINGTON, N.C., April 11 /PRNewswire/ -- Laboratory Corporation of
 America(R) Holdings (LabCorp(R)) (NYSE:   LH) today announced that
 Thomas P. Mac Mahon, chairman and chief executive officer, is scheduled to
 speak at the Merrill Lynch Health Services Conference in Washington, DC on
 Wednesday, April 11.
     At the conference, Mr. Mac Mahon will reiterate Company guidance for 2001,
 as filed in an 8K on February 14, 2001.  Mr. Mac Mahon will state,  "We expect
 revenue growth of 10 percent to 11 percent, with a bad debt rate of
 9.7 percent of sales, EBITDA margins of approximately 20.5 percent to
 21 percent of sales, and EPS growth of approximately 45 percent to
 50 percent."
     The first clinical laboratory to fully embrace genomic testing, Laboratory
 Corporation of America(R) Holdings (LabCorp(R)) has been a pioneer in
 commercializing new diagnostic technologies.  As a national laboratory with
 annual revenues of $1.9 billion in 2000 and over 18,000 employees, the company
 offers more than 4,000 clinical tests ranging from simple blood analyses to
 sophisticated molecular diagnostics.  Serving over 200,000 clients nationwide,
 LabCorp leverages its expertise in innovative clinical testing technology with
 its Centers of Excellence.  The Center for Molecular Biology and Pathology, in
 Research Triangle Park (RTP), North Carolina, develops applications for
 polymerase chain reaction (PCR) technology.  LabCorp's National Genetics
 Institute in Los Angeles is an industry leader in developing novel, highly
 sensitive PCR methods for testing hepatitis C and other infectious agents, and
 its Center for Esoteric Testing in Burlington, North Carolina, performs the
 largest volume of specialty testing in the network.  LabCorp's clients include
 physicians, state and federal government, managed care organizations,
 hospitals, clinics, pharmaceutical and Fortune 1000 companies, and other
 clinical laboratories.
     Each of the above forward-looking statements is subject to change based on
 various important factors, including without limitation, competitive actions
 in the marketplace and adverse actions of governmental and other third-party
 payors.  Further information on potential factors that could affect LabCorp's
 financial results is included in the Company's Form 10-K for the year ended
 December 31, 2000 and subsequent SEC filings.
 
 SOURCE  Laboratory Corporation of America Holdings